
|Videos|October 28, 2020
Clinical Cases in Relapsed and Refractory DLBCL
Author(s)Targeted Oncology
Experts review clinical cases and best practices for managing relapsed/refractory DLBCL.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Iberdomide, the First CELMoD for Relapsed/Refractory Multiple Myeloma
2
With 4 Guideline-Preferred Options, CNS Activity Is Deciding Frontline ROS1+ NSCLC Therapy
3
FDA Grants Breakthrough Device Designation to Blood-Based Lung Cancer Screening
4
Zipalertinib Combo Meets PFS End Point in First-Line EGFR Exon 20+ NSCLC
5





































